Abstract. Azimilide dihydrochloride (or azimilide) is a class III antiarrhythmic drug currently under investigation that has been tested in atrial fibrillation in four randomized, placebo-controlled clinical trials to assess efficacy and dose range. These investigational trials showed that doses of azimilide 100 and 125 mg once daily prolonged the time to symptomatic arrhythmia recurrence in patients with a history of symptomatic atrial fibrillation, atrial flutter or both. Doses of 75 mg or less were not useful in this indication.
Successful antiarrhythmic drug therapy remains one of the major challenges in the management of heart disease. Azimilide dihydrochloride (azimilide) is emerging as a potentially important new therapy in this field, and its development has been reviewed recently [1] . It is a Class III antiarrhythmic drug that blocks both I Kr and I Ks [2] . It has been tested in several randomized clinical trials of patients with both supraventricular and ventricular arrhythmias.
Efficacy

Clinical trials of patients with supraventricular arrhythmias
Azimilide was tested in 4 completed randomized, placebo-controlled clinical trials of patients with supraventricular arrhythmias (designated SVA1-SVA4). These trials tested azimilide doses of 35, 50, 75, 100 and 125 mg given once daily (QD) versus placebo. Each of the 4 trials included 2 strata, one stratum for patients with atrial fibrillation or atrial flutter (n = 1380 patients total among the 4 trials) and the other stratum for patients with paroxysmal supraventricular tachycardia (PSVT, n = 193 patients among the 4 trials) [3, 4] . All the trials measured time to the patient's first recurrence of symptomatic arrhythmia (atrial fibrillation, atrial flutter or paroxysmal supraventricular tachycardia) as the primary outcome variable.
Atrial fibrillation and atrial flutter stratum
The entry criteria for this stratum in all 4 studies required that patients have a history of symptomatic atrial fibrillation, atrial flutter or both that had been documented by ECG within 24 months prior to enrollment; that they continued to have symptoms of their arrhythmia; and that antiarrhythmic drug therapy was indicated in the judgment of the physician-investigator treating them. Almost all patients in this stratum had atrial fibrillation; a very few had atrial flutter as their only arrhythmia. Blinded treatments were assigned randomly and were started when patients were in sinus rhythm; almost all patients had therapy initiated as outpatients. The test treatment was given twice daily for 3 days to "load" the patient with azimilide and then given QD for the remainder of the protocol treatment period (Table 1, The most interesting of these 4 studies was SVA3 that was designed to both explore the effective dose range and demonstrate efficacy in a single large randomized trial with a placebo treatment group and 3 groups receiving azimilide 50, 100 or 125 mg (Table 1) [5]. The azimilide 125 mg dose group showed strong and significant efficacy compared with placebo in lengthening the time to first symptomatic arrhythmia recurrence. The median time to first arrhythmia recurrence was 17 days in the placebo group and 130 days in the azimilide 125 mg dose group (Figure 1) ; the hazard ratio for risk of recurrence on placebo compared with this azimilide dose was 1.83 and the 95 percent confidence interval (95% CI) was (1.24, 2.79; p = 0.002) [5] .
SVA3 also tested 2 lower doses of azimilide. The azimilide 100 mg dose group in this study had a median time to first symptomatic arrhythmia recurrence of 41 days (compared with 17 days in the placebo group). The hazard ratio was 1.38 (95% CI 0.96, 1.98; p = 0.08), an interesting improvement, albeit not statistically significant. The 50 mg dose group was not significantly different from placebo ( p = 0.37).
The atrial fibrillation and atrial flutter stratum from the other 3 studies provided additional information (Table 1) . Azimilide doses of 35 and 75 mg were each included in the SVA2 study, and both were too low to have meaningful efficacy in patients with these arrhythmias. The 100 mg dose was also studied in SVA1 and the 125 mg dose in SVA4. The hazard ratio for the 100 mg dose in SVA1 was 1.32 (95% CI 0.91, 1.97; p = 0.15), approximately equal to the value observed for this dose in the SVA3 trial. Neither SVA1 nor SVA3 by itself, however, had sufficient statistical power to conclusively detect a treatment
